Simplex Trading, LLC Aravive, Inc. Transaction History

Simplex Trading, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 02, 2024	BUY	$0.11 - $0.22 $1,341 - $2,682	12,193 Added 84.15%	26,682 $3,000
Q3 2023 Nov 01, 2023	BUY	$0.11 - $1.76 $1,593 - $25,500	14,489 New	14,489 $1,000
Q2 2022 Aug 03, 2022	SELL	$0.93 - $1.9 $14,109 - $28,826	-15,172 Reduced 99.8%	31 $0
Q1 2022 May 02, 2022	BUY	$1.85 - $2.75 $22,520 - $33,475	12,173 Added 401.75%	15,203 $29,000
Q4 2021 Feb 23, 2022	BUY	$2.19 - $4.07 $1,662 - $3,089	759 Added 33.42%	3,030 $6,000
Q3 2021 Oct 28, 2021	BUY	$3.67 - $5.8 $289 - $458	79 Added 3.6%	2,271 $13,000
Q2 2021 Aug 12, 2021	BUY	$4.65 - $6.42 $8,314 - $11,478	1,788 Added 442.57%	2,192 $13,000
Q1 2021 Apr 26, 2021	BUY	$5.11 - $9.24 $2,064 - $3,732	404 New	404 $2,000
Q4 2020 Feb 02, 2021	SELL	$4.36 - $6.51 $1,090 - $1,627	-250 Closed	0 $0
Q3 2020 Oct 14, 2020	SELL	$4.7 - $12.06 $14 - $36	-3 Reduced 1.19%	250 $1,000
Q2 2020 Jul 13, 2020	BUY	$5.18 - $14.81 $1,310 - $3,746	253 New	253 $0
Q1 2020 Apr 29, 2020	SELL	$3.5 - $13.77 $486 - $1,914	-139 Closed	0 $0
Q3 2019 Oct 15, 2019	BUY	$5.2 - $8.68 $520 - $868	100 Added 256.41%	139 $0
Q1 2019 Apr 18, 2019	BUY	$3.35 - $8.27 $130 - $322	39 New	39 $0

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.